AR-2114 Small Molecule Proprietary

CAF

Current Stage: Hit to Lead

Hit Discovery

Lead Optimization

Preclinical

Clinical

Indication (EN)

CAF

Modality

Small Molecule

Program Type

Proprietary

Interested in Collaboration?

If this program aligns with your therapeutic area, we would be glad to explore partnership opportunities.

Contact Us bd@arontier.co

Back to Pipeline